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Abstract
Objectives—To examine whether an accurate measure (using a gold-standard method) of total 
body fat (BF) would be a better predictor of cardiovascular disease (CVD) mortality than body 
mass index (BMI).
Participants and Methods—A total of 60,335 participants were examined between January 1, 
1979, and December 31, 2003, and then followed-up for mean of 15.2 years. BMI was estimated 
by standard procedures. Indices of body composition [i.e. BF%, fat mass index (FMI), fat-free 
mass (FFM) and FFM index (FFMI)] were derived from either skinfold thicknesses or hydrostatic 
weighing. For exact comparisons, the indices studied were categorized identically using sex-
specific percentiles.
Results—Compared with a medium BMI, a very high BMI was associated with hazard ratios 
(HR) of 2.7 (confidence interval, CI:2.1-3.3) for CVD mortality, a stronger association than for BF
% or FMI; i.e. HR=1.6(CI:1.3-1.9) and 2.2(CI:1.8-2.7), respectively. Compared with a medium 
FFMI, a very high FFMI was associated with a HR of 2.2 (CI:1.7-2.7) for CVD mortality, with 
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these estimates being markedly smaller for FFM, i.e. HR=1.2(CI:0.9-1.6). When the analyses were 
restricted only to the sample with hydrostatic assessments (N=29,959), the results were nearly 
identical, with even slightly larger differences in favor of BMI, i.e. HR=3.0 (CI:2.2-4.0) compared 
with BF% and FMI, i.e. HR=1.5(CI:1.2-1.9) and 2.1(CI:1.6-2.7) respectively. We estimated 
Harrell c-index as an indicator of discriminant/predictive ability for these models and observed 
that the c-index in models including BMI was significantly higher than that in models including 
BF% or FMI (all P values <.005).
Conclusions—The simple and inexpensive measure of BMI can be as clinically important or 
even more than total adiposity measures assessed by accurate and expensive methods. 
Physiological explanations for these findings are discussed.
INTRODUCTION
Obesity is a major public health concern in most of countries around the world. There is a 
vast amount of data supporting an increased risk of cardiovascular disease (CVD) mortality 
and reduced survival associated with overweight and obesity. Although this notion is 
generally well-accepted in public health and clinical settings, literature on this topic is 
extremely controversial. In fact, a number of studies have recently reported that in certain 
conditions, especially in individuals with existing CVD, obesity might be related with a 
lower risk of mortality, the so-called “obesity-mortality paradox”1. In addition, the 
systematic review and meta-analysis conducted by Flegal and colleagues concluded that 
overweight is associated with a reduced risk of mortality compared with normal-weight, 
whereas mild or Class I obesity was associated with a trend for better survival 2. Recently, 
Ahima and Lazar discussed this phenomenon and concluded that the impact of a high body 
mass index (BMI) on mortality is in question and that better metrics are needed 3. Before 
investigating which are the best indexes to measure obesity in relation to future health, the 
fundamental question of what obesity really means deserves discussion. While many 
scientists and other readers would assert that obesity means an excess of adiposity, measured 
by body fat percentage (BF%), others would suggest that most of what we currently know 
about the adverse effects of obesity on health is actually based on BMI-defined obesity. 
Therefore, obesity could as well mean an excess of body weight, which is what BMI directly 
measures.
Although it is internationally and well-accepted that the definition of obesity is based on 
BMI (i.e. 30 kg/m2 or higher), this traditional anthropometric index is strongly criticized for 
its lack of ability to distinguish between fat and lean tissues. There is no doubt that BMI 
includes an estimation error when assessing total adiposity. Based on this and on the 
assumption that it is the excess of adiposity that predicts mortality, it would be expected that 
more accurate measures of total adiposity, such as BF% or fat mass index [FMI, fat mass 
(kg) divided by squared height (m2)] would be stronger predictors of death than BMI. We 
reviewed the literature on this topic and searched whether there was any study conducting a 
direct comparison of BMI and BF% as predictors of CVD mortality or all-cause mortality. 
We found that most longitudinal studies examining mortality outcomes have used BMI as an 
exposure, for a simple reason, weight and height are easy and inexpensive to measure. In 
addition, in order to conduct exact comparisons, both variables should be handled 
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statistically in an identical way (e.g. sex-specific centiles); using standard cut-points (e.g. 
BMI ≥30kg/m2 and BF% ≥25 for men or ≥ 35 % for women for obesity) would lead to a 
different distribution of participants into the BMI and BF% groups, which would hamper 
accurate and direct comparisons. In this context, the Aerobics Center Longitudinal Study 
(ACLS) includes an accurate measure of total BF (i.e. using a gold-standard method in 
roughly 30,000 men and women) as well as BMI in the baseline examination 4-6, providing a 
unique opportunity to address this research question. The present study, therefore, aimed to 
examine whether an accurate measure of total BF would be a better predictor of CVD 
mortality and all-cause mortality than BMI. In addition, we tested which of the following 
conditions more strongly predict CVD mortality and all-cause mortality: an excess of body 
weight, an excess of BF or an excess of fat-free mass (FFM).
METHODS
Study Cohort
The ACLS is a prospective epidemiologic investigation of adult men and women 5,7,8; 
participants are mostly Caucasian (98%), well-educated, and worked in executive or 
professional positions 9. All participants completed a detailed questionnaire and underwent 
an extensive clinical evaluation, including a physical examination, fasting blood chemistry 
analyses, personal and family health history, body composition, smoking and alcohol use, 
and a maximal exercise treadmill test between January 1, 1979 and December 31, 2003. All 
participants provided written informed consent, and the study protocol was approved 
annually by the Institutional Review Board of the Cooper Institute. Exclusion criteria for the 
present analyses were: 1) existing CVD or cancer at baseline (n=1,021); 2) < 1 year of 
follow-up (n=1,064); 3) incomplete data on BMI, BF% and all the confounders (n=1,272). 
The rationale why participants with less than 1 year of follow-up were excluded is based on 
the fact that persons dying during the first year are likely to have a preexisting occult disease 
that confounds the relation between the risk factor under study and mortality. Excluding 
persons dying during the first years of follow-up purportedly reduces this confounding 
effect, and is a widely used technique especially in the field of obesity 10. Based on these 
criteria, a total of 3,357 participants (5.3%) aged 20 years or older at baseline were 
excluded. The final sample included 60,335 participants (26.7% women) for the analyses.
Baseline Examination
As described previously 7, height and weight were measured using a stadiometer and a 
standard scale. Waist circumference was obtained at the level of the umbilicus with a plastic 
anthropometric tape. BMI was calculated as weight in kilograms divided by height in meters 
squared (kg/m2); BF% was assessed by hydrostatic weighing or the sum of 7 skinfold 
measures, following standardized protocols 4,11. Some participants had an underwater 
weighing assessment for hydrostatically estimated body density with a mathematical 
conversion to BF%, whereas other participants were assessed using standard skinfold 
thicknesses from which BF% was estimated. Standardized protocols used and specific 
procedures for the ACLS assessment of BF% were published elsewhere 4,5,12,13. A large 
number of the participants (N=21,681) had both measurements, and the correlation between 
hydrostatically estimated BF% and skinfold estimated BF% was >0.90 12,13. When 
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available, hydrostatically estimated BF% was always used in the analysis, i.e. hydrostatic 
weighing was available on 52% of the sample. In the present study, the analyses were 
conducted for the whole sample (including participants assessed with both methods) and 
also for the sub-sample with hydrostatic weighing. For the purpose of this study and in order 
to conduct as exact as possible comparisons with BMI, we additionally computed FMI 
(kg/m2), as fat mass expressed in kilograms divided by the square of height expressed in 
meters. For exploratory analyses, we also computed FFM expressed in kg by subtracting fat 
mass (kg) from total body weight (kg). Likewise, for exact comparisons with BMI, FFM 
index (FFMI, kg/m2) was computed as FFM expressed in kilograms divided by the square of 
height expressed in meters. FMI and FFMI body composition indexes are widely used in the 
literature 14-16 and of special interest for this study, since they mirror the way BMI is 
computed and expressed, i.e. dividing weight, fat mass or FFM by squared height expressed 
in meters. Comparing the findings obtained for BMI, FMI and FFMI will allow testing of 
the following to determine what more strongly predicts CVD mortality and all-cause 
mortality: an excess of body weight, an excess of BF or an excess of FFM, which is the 
secondary aim of this study.
Information on risk factors such as smoking (current smoker or not current smoker), 
excessive drinking (defined as alcohol drinks >14 per week for men and >7 per week for 
women), physical inactivity (defined as no leisure-time physical activity during past three 
months) and having a parental history of CVD or cancer was obtained from a standardized 
medical history questionnaire. As described previously7,17, cardiorespiratory fitness (CRF) 
was defined as the total time of a symptom-limited maximal treadmill exercise test, using a 
modified Balke protocol. Total time of the test on this protocol correlates highly with 
measured maximal oxygen uptake (VO2max) in both men (r = 0.92)18 and women (r = 
0.94)19. The test endpoint was volitional exhaustion or when the physician stopped it for 
medical reasons. VO2max was calculated from the final treadmill speed and grade20.
As described previously6,21, systolic and diastolic blood pressures were obtained with a 
mercury sphygmomanometer and auscultory methods following the American Heart 
Association protocol22. A fasting blood sample was obtained by venipuncture and serum 
total cholesterol was assayed with automated techniques at the Cooper Clinic Laboratory, 
which participates in and meets the quality control standards of the U.S. Centers for Disease 
Control and Prevention Lipid Standardization Program.
Assessment of outcomes
The main outcome of this study is CVD mortality, yet results about all-cause mortality were 
also reported as Online-Only Supplemental Material in order to provide a broader picture 
about the association between body composition markers and mortality. The participants 
were followed from the baseline examination until the date of death or 31 December 2003. 
Mortality surveillance was based on the National Death Index (NDI). Participants not found 
to be deceased as of December 31, 2003 via the National Death Index were assumed to be 
alive. The underlying cause of death was determined from the NDI report or by a 
nosologist’s review of official death certificates allobtained from the department of vital 
records in the decedent’s state of residence. Cardiovascular disease mortality was defined by 
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International Classification of Diseases, Ninth Revision (ICD-9) codes 390 to 448.9 before 
1999 and Tenth Revision (ICD-10) codes I00 to I78 during 1999-200323.
Statistical analysis
All statistical analyses were performed using IBM-SPSS, version 20.0 SPSS Inc., Chicago, 
IL, USA. The level of significance was set at <0.05 for all the analyses. The characteristics 
of the study sample are presented as means and standard deviations or as frequencies and 
percentages, as appropriate. In order to address the main study aim, we used Cox 
proportional hazards regression (two-sided tests) to estimate hazard ratios (HRs) and 95% 
confidence intervals (CIs) according to exposure categories. The main study outcome was 
CVD mortality, yet results for all-cause mortality are also provided in Supplemental Figure 
1. The exposures/predictors studied were BMI, BF%, FMI, FFM and FFMI. They all were 
categorized using exactly the same procedures in order to allow exact comparisons among 
exposures. These variables were categorized based on sex-specific centiles as follows: Very 
low if < percentile 5th, Low if percentile 5th-15th, Middle if percentile 15th-85th, High if 
percentile 85th-95th and Very high if above percentile 95th. Percentiles 85th and 95th have 
been traditionally used to represent overweight and obesity respectively, so we used the 
same criteria for all the indices studied and mirrored the bottom extreme using percentiles 
5th and 15th. The possibility of an interaction with sex was tested by entering interaction 
terms (e.g. sex×BMI) in all the models. Since no evidence of interaction with sex was 
observed for any of the models performed (all P>.2), all the analyses were conducted for the 
whole sample together. All the analyses were adjusted for age, sex, examination year, 
smoking, alcohol consumption, physical inactivity and parental history of CVD (and 
parental history of cancer, when all-cause mortality was the outcome studied). In order to 
test the discriminating ability of the predictive models used, we estimated the c-index as 
proposed by Harrell et al.24,25 for each of the models including BMI, BF% and FMI and 
compared whether these c-indices were significantly different from each other using the 
“compareC” package in the R statistical software, following the method recently suggested 
by Kang and colleagues 26.
A number of sensitive/exploratory analyses were conducted, in order to test whether the 
results from the main analyses were altered in specific conditions/sub-groups of individuals: 
1) in the subsample with hydrostatic weighing assessment; and 2) in a subsample of 
individuals with high WC. We also tested how additional adjustment for CRF, hypertension 
or hypercholesterolemia influenced the results.
RESULTS
Table 1 shows the descriptive characteristics of the study sample at baseline (N=60,355): 
13% of the participants were obese and 18% of them centrally obese; 16% of the 
participants were smokers and 8% of them drank excessive alcohol. One third of them were 
inactive and one fourth had parental history of CVD disease. One fifth of the participants 
had hypertension or hypercholesterolemia. Over a mean follow-up period of 15.2 years, a 
total of 3,780 (6.3%) participants died, 1,359 due to CVD (2.3% of the total sample and 36% 
of the total number of deaths).
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Compared with a medium BMI, a very high BMI was associated with 2.7-fold higher risk 
(CI:2.1-3.3) of CVD mortality (Figure 1). The corresponding HRs for CVD mortality for BF
% and FMI were lower than for BMI, and were lower for BF% than for FMI, i.e. 1.6 (CI:
1.3-1.9) and 2.2 (CI:1.8-2.7) respectively. When the analyses were restricted only to the 
sample with hydrostatic assessments (N=29,595), the results were very similar (Figure 1) 
with even slightly larger differences in favor of BMI, i.e. HR=3.0 (CI:2.2-4.0) compared 
with BF% and FMI, i.e. HR=1.5(CI:1.2-1.9) and 2.1(CI:1.6-2.7) respectively. The diagnostic 
ability (c-index) of the multivariate model including BMI to predict CVD mortality was 
0.844 in the whole sample, whereas the same multivariate model but with BF% was 0.839 
(P<0.001 for c-index difference compared with the BMI model) and with FMI was 0.841 
(P=0.004 for c-index difference compared with the BMI model). The corresponding c-
indices for models including BMI, BF% and FMI in the subsample with hydrostatic 
weighing assessment were 0.828, 0.820 and 0.823 respectively; with c-indices of BF% and 
FMI being significantly different from those of BMI (P<0.001 and P=0.005 respectively).
Compared with a medium FFMI, a very high FFMI was associated with 2.2 (CI:1.7-2.7) 
higher risk of CVD mortality, with these estimates being markedly smaller for FFM, i.e. 
1.2(CI:0.9-1.6); Figure 2. Similar results were obtained when the analyses were conducted 
on the sub-sample with hydrostatic assessments (Figure 2).
Table 2 shows the sex-specific (percentile-based) levels of weight, fat or FFM corresponding 
to the study groups used in this study. A very high (percentile 95th) BMI was considered if a 
BMI equal or higher than 34kg/m2 for men and 32kg/m2 for women. A very high BF% was 
considered if a BF% equal or higher than 33% for men and 39% for women. A very high 
FMI was considered if a FMI equal or higher than 11 for men and 12 for women; and a very 
high FFMI was considered if a FFMI equal or higher than 25 for men and 21 for women. As 
shown in Figures 1 and 2, these cut-point values were associated with a higher risk of CVD 
mortality.
HRs and CIs for all-cause mortality are shown in Supplemental Figure 1as Online-Only 
Supplemental Material. Overall, the differences in HRs for BMI compared with BF% or 
FMI were smaller for all-cause mortality than for CVD mortality.
Sensitivity/exploratory analyses
We run the same models as in Figure 1 in a sub-sample of individuals with a high WC (i.e. 
n=7,887) in order to test whether the results would change in a sample of apple shaped 
individuals, in which body fat markers could potentially be more strongly related to the risk 
of CVD mortality. The differences between BMI and adiposity markers persisted, HRs (and 
its CIs) for very high BMI were markedly larger than those of very high levels of either BF
% or FMI (See Supplemental Table 1). In addition, we tested whether the proportion of 
missing values for WC was equal in men and women, and it was not. There were more 
missing data (proportionally) in women (33%) than in men (24%), P<0.001. In order to test 
whether the missing data on WC could influence the main study findings, we run again all 
the main models in a subsample with valid data on WC, and also in the subsample assessed 
with hydrostatic assessment with valid data on WC. In all cases, the HRs associated with 
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CVD mortality were higher for very high BMI than for very high BF% or FMI, when 
compared with the respective middle groups.
We also run the models (same exposures and outcomes as in Figures 1 and 2) with additional 
adjustment for CRF (VO2max). All the HRs were attenuated as a result of this additional 
adjustment (Supplemental Table 2); nevertheless, a very high BMI persisted associated with 
a 1.6 (CI: 1.3-2.1) higher risk of CVD mortality compared with middle levels of BMI, being 
the corresponding HRs for BF% 1.0 (CI: 0.9-1.3) and for FMI 1.3 (CI: 1.1-1.6). 
Interestingly, a very high FFM and FFMI also remained significantly related to higher CVD 
mortality after additional adjustment for CRF, i.e. HR=1.4 (CI: 1.0-1.8) and HR=1.6 (CI: 
1.3-2.1) respectively. Likewise, additional adjustments for hypertension attenuated all the 
HRs, yet differences between BMI models and BF% or FMI persisted (See Supplemental 
Table 3). On the other hand, the results were not altered after additional adjustment for 
hypercholesterolemia (data not shown).
DISCUSSION
Main findings
The present study contributes to the existing knowledge with several major findings, which 
have implications for clinical practice and public health applications, as well as for the 
fundamental understanding of obesity and its adverse consequences. First, the main findings 
were directly related to daily clinical practice and epidemiology: a) BMI was a stronger 
predictor of CVD mortality than total adiposity markers, particularly BF% and FMI, 
assessed with accurate methods (including a gold-standard); b) if total adiposity is to be 
assessed, FMI is far more predictive of CVD mortality than BF%. Second, concerning our 
current understanding of what obesity means, this study provides the following novel 
findings: a) we used BMI, FMI and FFMI as indicators of body weight, fat and FFM, 
respectively normalized by height, and our results supported the notion that an excess of 
body weight is more associated with a worse CVD prognosis than is an excess of total BF; 
b) in addition, not only is an excess of BF related with higher risk of CVD mortality, but also 
and to a similar extent an excess of FFM increases CVD mortality risk. The results are very 
consistent and persisted in all the sensitivity/exploratory analyses conducted. The differences 
between the models including BMI and those including BF% or FMI were present: 1) when 
the analyses were conducted in the whole sample and in the sub-sample with hydrostatic 
weighing assessment, as well as in the sub-sample with a high WC. 2) after additional 
adjustment for CRF, hypertension or hypercholesterolemia. Finally, the fact that the c-index 
observed for the model including BMI was significantly higher than for the models 
including BF% or FMI, support the notion than BMI might be a stronger predictor of CVD 
mortality than markers of total adiposity measured using gold-standard methods.
Physiological interpretation of the findings
If body weight is the sum of fat mass plus FFM, and a high body weight (normalized by 
height, i.e. high BMI) predicted CVD mortality more strongly than a high fat mass 
(normalized by height, i.e. high FMI), the most logical explanation for this finding would be 
that the remaining part of body weight, i.e. the FFM, is also contributing to the larger effect 
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size associated with a high BMI. This notion is supported by our results by showing that a 
high FFMI (FFM normalized by height) was associated with higher risk of CVD mortality to 
a similar extent that a high FMI, so that high FMI plus high FFMI result in a high BMI that 
provides the strongest prediction of CVD mortality.
When interpreting these findings, it is important to bear in mind that obese individuals 
(defined by the internationally accepted BMI>30kg/m2) are not only heavier and fatter than 
their normal-weight peers but also have higher levels of FFM 27-29, a human adaptation to 
the extra load (body weight) that these individuals have to carry during their daily life 
activities. This fact together with the principles of pathophysiology and hemodynamics of 
CVD in relation to obesity provide a solid mechanistic explanation to our findings. The 
higher FFM largely explains the higher circulating blood volume that has been observed in 
obese individuals. This increases the left ventricular stroke volume which in turns increases 
the cardiac output. These changes place an extra burden on the heart resulting in ventricular 
(both left and right) alterations that ultimately lead to ventricular (both left and right) 
hypertrophy and enlargement, predisposing obese people to heart failure. More detailed 
information about obesity and its relationship with pathophysiology and hemodynamics of 
CVD is provided elsewhere 1,30,31.
The role of high fat mass in CVD has been more extensively studied. First, it is well-known 
that this worsens most of the CVD risk factors, such as plasma lipids, blood pressure, 
glucose and inflammation. In addition, it increases the risk of sleep apnea, which ultimately 
is associated with right ventricular hypertrophy and enlargement, increasing the risk of right 
ventricular failure 1. Our findings are supported by other studies that observed a positive 
association between FFM/lean mass and CVD risk factors in young people 32-35. Bigaard 
and colleagues36 observed a reversed J-shape association between FFMI and all-cause 
mortality, using bioelectrical impedance to assess body composition and additionally 
adjusting by FMI what could have attenuated the association since it is known that obese 
people have both high fat mass and high FFM. Recently, Moreno et al.,37 have demonstrated 
that lean mass rather than fat mass is an independent determinant of carotid intima media 
thickness in obese subjects, which would contribute to explain the higher risk in CVD 
mortality observed in our study in individuals with a very high FFMI. Pooling all this 
evidence together, the accumulated physiological consequences of high FFM and high fat 
mass for CVD can explain why BMI, which includes both FFM and fat mass (in fact, BMI is 
the mathematical sum of FMI + FFMI), can be a stronger predictor than these two 
components of body composition separately. These findings and pathophysiology 
explanations might lead to a change in the understanding of obesity. Obesity might be 
considered as an excess of body weight (which includes the fat and non-fat components), 
rather than an excess of adiposity alone. In addition, BMI has been strongly criticized by its 
lack of ability to distinguish between fat and non-fat components; our findings, however, 
show that BMI, by including both components together, might be more clinically 
meaningful than accurate measures (including gold-standard methods) of the fat component 
alone. In line with our findings and interpretations, Dr. Wells, a well-known expert on body 
composition analysis, recently pointed out that “BMI is not a good index of adiposity, but 
might be a good index of cardio-metabolic risk” 38. Figure 3 presents a graphical view of the 
main study findings, as well as our physiological interpretations.
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Finally, it is important to mention that the interpretation of the findings largely differ when 
we are referring to apparently healthy people, as it is the case in our study in which people 
with diagnoses of CVD or cancer at baseline were excluded from the analyses, compared 
with when we are referring to CVD patients or referral populations at baseline 40. In this 
second case, the so-called “obesity-mortality paradox” has been shown very 
consistently 1,40-44. In the current study, having a very high FMI and very high FFMI were 
both associated with higher risk of CVD mortality and all-cause mortality, whereas previous 
studies conducted in patients with stable coronary heart disease have shown the opposite 
trend, with high body fat combined with high FFMI was associated with the lowest risk of 
mortality 45.
Practical and clinical implications
The present study supports the use of BMI, a combination of fat mass and FFM, as a 
predictor of CVD prognosis. Of note is that this simple index was a stronger predictor of 
CVD than accurate measures of body composition, even when using a gold-standard 
method. This strongly supports the use of BMI in clinical epidemiology, which is in line 
with the recent AHA/ACC/TOS Guidelines for the Management of Overweight and Obesity 
in Adults 46. In order to do exact comparisons between the indexes used in this manuscript, 
we used our population-specific percentiles to define very high BMI. The percentile 95th 
used to define very high BMI corresponds with a BMI of 34 and 32kg/m2 for men and 
women, respectively, which in men is near to the international definition of Class II obesity 
(i.e. BMI>35kg/m2) and in women is near to Class I obesity (i.e. BMI>30kg/m2).
In addition, our results support the use of FMI instead of BF% and also the use of FFMI 
instead of FFM, showing that normalizing body composition components by squared height 
markedly increased their predictive capacity for CVD mortality. Based on these findings, 
whenever body composition components are to be assessed in relation to CVD prognosis, 
the use of FMI and FFMI is preferred to other markers traditionally used, such as BF%. The 
current study provides (Table 2) cut-points values for FMI and FFMI associated with a 
higher risk of CVD mortality, i.e. FMI equal or higher than 10.4 kg/m2 for men and 12.0 
kg/m2 for women; and FFMI equal or higher than 24.3 kg/m2 for men and 20.6 kg/m2 for 
women. Although these cut-points are population-specific, they seem to match well with 
those reported for other Caucasian populations 14,16. The US-representative data from 
NHANES for a 25 year-old adult Caucasian individuals measured by Dual X-ray 
Absorptiometry (DEXA) for FMI equivalent to Class II obesity (BMI>35kg/m2) was 11.9 
kg/m2 for men, while the FMI equivalent to Class I obesity (BMI>30kg/m2) was 12.9 kg/m2 
for women 16. Whenever possible, country-specific reference values are desired , and these 
NHANES cut-points 16 supported by the association with CVD mortality reported in the 
present study , which could be very useful for clinical practice in USA. Similarly, the 
reference data (including percentile 95th) for FMI and FFMI reported by Schutz et al. could 
be useful for European populations 14.
Limitations and strengths
The majority of the participants were Caucasian, well-educated and with high professional 
positions, so we cannot know to which extent the present findings apply to other 
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populations. Nevertheless, the main aim of the present study was to compare BMI with other 
body composition indexes in relation to CVD and all-cause mortality. Therefore, we believe 
that whether the study sample is more or less heavier and more or less fatter than the general 
US population or any other population is unlikely to have a major influence on the study 
conclusions. The number of women participating in the present study (N=16,101) is 
markedly smaller than the number of men (N=44,234), which is a limitation of the study. 
However, the fact that no interaction with sex was found suggests that the major findings 
hereby reported are consistent for both genders. We do not have information about where fat 
is located in the body, e.g. subcutaneous fat versus visceral fat what could influence CVD 
mortality. Since the methods used in this study do not allow to distinguish among different 
fat depots, we cannot examine whether all fat (e.g. intra-abdominal vs. subcutaneous) 
imparts the same risks.
The major strength of the present study is the use of a gold standard measure of body 
composition (i.e. hydrostatic weighing) in roughly 30,000 participants of whom a complete 
baseline examination and mortality outcomes were available. In addition, 21,681 participants 
were assessed with both methods (i.e. hydrostatic weighing and skinfolds) allowing to 
conduct cross-validation between methods (r>0.9) and resulting in good estimates of body 
composition for a sample of more than 60,000 participants. These data provided a unique 
opportunity to address the current study questions.
Conclusions
We make two major conclusions from these analyses:
1. Our data support that BMI is a stronger predictor of CVD mortality compared with 
accurate measures of adiposity, such as BF% and FMI. This suggests that the 
simple and inexpensive measure of BMI can be as clinically important measure or 
even more than total adiposity measures assessed by accurate, complex and 
expensive methods. Another major conclusion of this study is that FMI is a more 
informative measure of future CVD prognosis than is BF%. This has direct 
implications for clinical settings.
2. Considering a very high BMI as an indicator of an excess of body weight 
(normalized by height) and FMI as an indicator of an excess of BF (equally 
normalized by height), the results presented in this study suggest that an excess of 
body weight is a stronger predictor of CVD mortality than is an excess BF. In 
addition, our results support that an excess of FFM, and specially FFMI, is also 
associated with a higher risk of CVD mortality (as much as an excess of BF), which 
could explain why BMI (the mathematical sum of FMI + FFMI) can be a stronger 
predictor of CVD mortality than fat mass alone.
These findings have potentially important implications for current clinical practice, future 
research, as well as for general understanding obesity and its adverse consequences.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hazard ratios for mortality due to cardiovascular disease (CVD) according to body 
mass index (BMI), percent body fat (BF%) and fat mass index (FMI) groups in the whole study 
sample (N=57,910) and in the sub-sample with hydrostatic weighing assessment (N=29,959)
Body weight/body fat groups were estimated based on sex-specific centiles: Very low if < 
percentile 5th, Low if percentile 5th-15th, Middle if percentile 15th-85th, High if percentile 
85th-95th and Very high if above percentile 95th.
All the models were adjusted for age, sex, examination year, smoking, alcohol consumption, 
inactivity and parental history of CVD.
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Figure 2. Hazard ratios for mortality due to cardiovascular disease (CVD), according to fat-free 
mass (FFM) and to fat-free mass index (FFMI) groups in the whole study sample (N=57,910) and 
in the sub-sample with hydrostatic weighing assessment (N=29,959)
FFM and FFMI groups were estimated based on sex-specific centiles: Very low if < 
percentile 5th, Low if percentile 5th-15th, Middle if percentile 15th-85th, High if percentile 
85th-95th and Very high if above percentile 95th.
All the models were adjusted for age, sex, examination year, smoking, alcohol consumption, 
inactivity and parental history of CVD.
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Figure 3. Graphical illustration of the main findings of the present study and plausible 
physiological interpretation
BMI indicates body mass index; BF%, percent body fat; FMI, fat mass index; FFM, fat-free 
mass; FFMI, fat-free mass index; CVD, cardiovascular disease; LV, left ventricular; RV, right 
ventricular. Part of the physiological interpretation shown is adapted with permission from 
Lavie et al. 30. More detailed information about obesity and its relationship with 
pathophysiology and hemodynamics of CVD is provided elsewhere 1,30,39.
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